Candel Therapeutics earnings were -$50.0M for the trailing 12 months ending Jun 30, 2024, with N/A growth year over year. The latest CADL earnings report on Jun 30, 2024 announced Q2 2024 earnings of -$22.2M, up 170.5% from last quarter. For the last reported fiscal year 2023 ending Dec 31, 2023, CADL reported annual earnings of -$37.9M, with 101.9% growth.
Candel Therapeutics Earnings Reports & History FAQ
What were Candel Therapeutics's earnings last quarter?
Candel Therapeutics (NASDAQ: CADL) reported Q2 2024 earnings per share (EPS) of -$0.74, up 124.24% year over year. Total CADL earnings for the quarter were -$22.24 million. In the same quarter last year, Candel Therapeutics's earnings per share (EPS) was -$0.33.
Is Candel Therapeutics profitable or losing money?
As of the last Candel Therapeutics earnings report, Candel Therapeutics is currently losing money. Candel Therapeutics's net profit (also called net income) for the twelve months ending Jun 30, 2024 was -$49.99 million, a 55.34% increase year over year.
What was CADL's earnings growth in the past year?
As of Candel Therapeutics's earnings date in Q4 2024, Candel Therapeutics's earnings has grown year over year. CADL earnings in the past year totalled -$49.99 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.